Physician profile
Patrick Edward Gilhool
NPI 1902848948
$13,302.15
in general payments reported to CMS, 2019-2025
52 companies · $2,724 in 2025
The $2,724 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,062 · 2020: $611 · 2021: $1,722 · 2022: $2,085 · 2023: $2,700 · 2024: $2,399 · 2025: $2,724.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,780 · Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,780.30 |
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,924.90 | 2019-2025 | Farxiga, Airsupra, Lokelma |
| Glaxosmithkline, LLC. | $1,606.14 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $1,285.04 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $1,106.71 | 2019-2025 | |
| Abbvie INC. | $1,101.54 | 2021-2025 | |
| Lilly USA, LLC | $883.81 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $474.34 | 2019-2024 | Xarelto |
| Astellas Pharma US INC | $374.23 | 2019-2025 | Veozah, Myrbetriq |
| Sanofi-Aventis U.S. LLC | $365.32 | 2019-2022 | |
| Abbott Laboratories | $302.70 | 2021-2025 | Freestyle Libre 3, Freestyle Libre |
| Otsuka America Pharmaceutical, INC. | $289.99 | 2021-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $261.66 | 2020-2025 | Gardasil 9, Capvaxive, Rotateq |
| Bayer Healthcare Pharmaceuticals INC. | $247.98 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $207.66 | 2020-2024 | Jardiance, Synjardy, Tradjenta |
| Mannkind Corporation | $199.77 | 2025 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Gilhool listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.